Navitor starts Part B of Phase l trial of NV-5138 to treat TRD - Drug Development Technology

Submitted by Anonymous (not verified) on Mon, 01/28/2019 - 00:00

Navitor starts Part B of Phase l trial of NV-5138 to treat TRD  Drug Development TechnologyNavitor Pharmaceuticals has commenced Part B of its Phase l clinical trial investigating NV-5138 for the treatment-resistant depression (TRD).